Altimmune, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Altimmune is in Stage 4, the downtrend phase, now in week 2 (since Oct 14, 2026). It closed at $2.17, 64.9% below its 52-week high and below its 200-day average, which is falling.

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. More about the company

$2.17

-2.69% today

$422M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S3 15w

S4 15w

S4 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 15w → S1 4w → S2 13w → S3 15w → S4 9w → S1 4w → S4 2w → S1 7w → S2 7w → S3 4w → S4 15w → S1 5w → S4 13w → S1 13w → S2 5w → S3 5w → S4 19w → S1 8w → S4 1w current

Total tracked: 165 weeks across 19 stage runs.

ALT among Biotechnology338th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…338	ALTAltimmune, Inc.	Stage 4 · wk 2	25	−32.0%

vs 52W High

-64.9%

$2.17 lo$6.18 hi

64.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-35.1%

200 DMA: $3.34 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.77x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-32.0%

-21.7%

-24.9%

YTD

-38.2%

-46.3%

Scan Membership

Breakout Watch

Latest: 2024-12-11

7 appearances in last 60 days. First seen: 2020-03-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.77x

2026-10-21S4

Wk 2 · Vol 1.13x

2026-10-20S4

Wk 1 · Vol 0.57x

2026-10-19S4

Wk 1 · Vol 0.64x

2026-10-16S4

Wk 1 · Vol 1.04x

2026-10-15S4

Wk 1 · Vol 0.82x

2026-10-14S41→4

Wk 1 · Vol 1.36x

2026-10-13S1

Wk 8 · Vol 0.89x

2026-10-12S1

Wk 8 · Vol 0.52x

2026-10-09S1

Wk 8 · Vol 0.63x

2026-10-08S1

Wk 8 · Vol 1.14x

2026-10-07S1

Wk 7 · Vol 0.69x

Moving averages & range

50 DMA

$2.93

200 DMA

$3.34

52W High

$6.18

52W Low

$2.17

5D Low

$2.17

Resistance levels (recent highs)

20d High

$3.06

60d High

$3.42

120d High

$3.42

250d High

$6.18

Next resistance

+41.0%

to 20d High

ROE

-28.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Altimmune: quick answers

What stage is Altimmune in?

As of Oct 22, 2026, Altimmune (ALT) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 14, 2026 and is in week 2. What the four stages mean

Is Altimmune in an uptrend?

No. Altimmune is in a Stage 4 downtrend. It trades 35.1% below its 200-day average, which is falling.

How far is Altimmune from its 52-week high?

Altimmune closed at $2.17 on Oct 22, 2026, 64.9% below its 52-week high of $6.18. Its 52-week low is $2.17.

How has Altimmune performed over the past year?

As of Oct 22, 2026, Altimmune is down 46.3% over the past year and down 38.2% so far in 2026.

Which sector and industry is Altimmune in?

Altimmune is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.